Australian Prescriber Podcast

Laura Beaton chats with David Brieger, head of cardiology at Concord Hospital, Sydney, about the 2025 Australian acute coronary syndromes [ACS] clinical guideline. David explains the importance of secondary prevention for ACS, including new approaches to tailoring the duration of dual antiplatelet therapies, new lipid targets, and the limited role of beta blockers and colchicine. Read the full article in Australian Prescriber.

In a follow-up to our episode on attention deficit hyperactivity disorder (ADHD) in children and adolescents, Justin Coleman talks to psychiatrist Shuichi Suetani about the pharmacological management of ADHD in adults. They discuss the different considerations for managing adults compared with children, as well as important adverse effects and monitoring of ADHD medications. Shuichi also outlines other factors to consider when assessing treatment response. Read the full article in Australian Prescriber.

Jo Cheah talks to Terri-Lynne South, Medical Director at Lifestyle Metabolic in Brisbane, about her paper on injectable drugs for weight management. Terri-Lynne outlines the available GLP-1 drugs and how they work in managing weight. The conversation also covers important considerations for prescribers, including off-label use, potential adverse effects and the need for behavioural and lifestyle modifications. Read the full article by Terri-Lynne and her co-author Natasha Yates in Australian Prescriber.

Justin Coleman chats with sexual health physician Louise Owen about her paper on HIV testing. The conversation covers who and when to test, including higher risk populations and indicator conditions, and the types of HIV tests available, such as rapid point-of-care testing. Read the full article in Australian Prescriber.

AP Podcast hosts David Liew and Dhineli Perera talk about Australia's top 10 drugs over the last year. They discuss the top drugs dispensed under the PBS, based on prescription count and cost to the government. They touch on changes to the use of certain drug classes such as oral anticoagulation, and the impact of the COVID pandemic on antiviral drug use. Read the full article for 2024-25 in Australian Prescriber.